Dan Sachs, MD files a patent on the idea that leads to ReActiv8.

The first subjects enrolled in our Feasibility Study.

A big year for our company: Submitted pre-IDE package to FDA, moved HQ to Dublin, and finished Feasibility Study enrollment.